FGI-104 is the name of an experimental broad-spectrum
antiviral drug
Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Unlike most antibiotics, antiviral drugs do n ...
, with activity against a range of viruses including
hepatitis B
Hepatitis B is an infectious disease caused by the ''Hepatitis B virus'' (HBV) that affects the liver; it is a type of viral hepatitis. It can cause both acute and chronic infection.
Many people have no symptoms during an initial infection. Fo ...
,
hepatitis C
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; it is a type of viral hepatitis. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, a ...
,
HIV
The human immunodeficiency viruses (HIV) are two species of ''Lentivirus'' (a subgroup of retrovirus) that infect humans. Over time, they cause acquired immunodeficiency syndrome (AIDS), a condition in which progressive failure of the immune ...
,
Ebola virus
''Zaire ebolavirus'', more commonly known as Ebola virus (; EBOV), is one of six known species within the genus ''Ebolavirus''. Four of the six known ebolaviruses, including EBOV, cause a severe and often fatal hemorrhagic fever in humans and ot ...
, and
Venezuelan equine encephalitis virus
Venezuelan equine encephalitis virus is a mosquito-borne viral pathogen that causes Venezuelan equine encephalitis or encephalomyelitis (VEE). VEE can affect all equine species, such as horses, donkeys, and zebras. After infection, equines may ...
.
Mechanism
The drug acts by inhibiting the protein
TSG101
Tumor susceptibility gene 101, also known as TSG101, is a human gene that encodes for a cellular protein of the same name.
Function
The protein encoded by this gene belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzy ...
, which transports newly manufactured virions to the exterior of an infected cell, thus breaking the replication cycle of the virus. In pre-clinical studies, FGI-104 has been shown to protect mice from
Ebola virus disease
Ebola, also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a viral hemorrhagic fever in humans and other primates, caused by ebolaviruses. Symptoms typically start anywhere between two days and three weeks after becom ...
.
See also
*
FGI-103
FGI-103 is an antiviral drug developed as a potential treatment for the filoviruses Ebola virus and Marburg virus. In tests on mice FGI-103 was effective against both Ebola and Marburg viruses when administered up to 48 hours after infection. Th ...
*
FGI-106
FGI-106 is a broad-spectrum antiviral drug developed as a potential treatment for enveloped RNA viruses, in particular viral hemorrhagic fevers from the bunyavirus, flavivirus and filovirus families. It acts as an inhibitor which blocks viral ent ...
*
LJ-001
LJ-001 is a broad-spectrum antiviral drug developed as a potential treatment for enveloped viruses. It acts as an inhibitor which blocks viral entry into host cells at a step after virus binding but before virus–cell fusion, and also irreversib ...
References
Antiviral drugs
Ebola
Quinolines
Chloroarenes
Phenols
Phenol ethers
Diethylamino compounds
Primary alcohols
{{antiinfective-drug-stub